U.S. Markets closed
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • Dow 30

    35,677.02
    +73.94 (+0.21%)
     
  • Nasdaq

    15,090.20
    -125.50 (-0.82%)
     
  • Russell 2000

    2,291.27
    -4.91 (-0.21%)
     
  • Gold

    1,793.10
    +11.20 (+0.63%)
     
  • EUR/USD

    1.1646
    +0.0015 (+0.1281%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • Vix

    15.43
    +0.42 (+2.80%)
     
  • GBP/USD

    1.3760
    -0.0036 (-0.2601%)
     
  • USD/JPY

    113.4800
    -0.5080 (-0.4457%)
     
  • BTC-USD

    61,026.42
    +441.07 (+0.73%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,804.85
    +96.25 (+0.34%)
     

Could Pfizer and Merck Be Big Winners With COVID Pills?

·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Both Pfizer (NYSE: PFE) and Merck (NYSE: MRK) have recently announced they're advancing oral antiviral candidates targeting COVID-19 into late-stage testing. In this Motley Fool Live video recorded on Sept. 8, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss if the two drugmakers could be big winners with their COVID-19 pills.